Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Consequences of delaying progression to optimal therapy in patients with type 2 diabetes not achieving glycemic goals.

Hsu WC.

South Med J. 2009 Jan;102(1):67-76. doi: 10.1097/SMJ.0b013e318182d8a2. Review.

PMID:
19077788
2.
3.

Emerging care for type 2 diabetes: using insulin to reach lower glycemic goals.

Feinglos MN, Bethel MA.

Cleve Clin J Med. 2005 Sep;72(9):791-9. Review.

PMID:
16193826
4.

Insulin management of type 2 diabetes mellitus.

Petznick A.

Am Fam Physician. 2011 Jul 15;84(2):183-90.

5.

Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus.

Yki-Järvinen H.

Diabetes Metab Res Rev. 2002 Sep-Oct;18 Suppl 3:S77-81. Review.

PMID:
12324990
6.

Pharmacological management of type 2 diabetes mellitus: rationale for rational use of insulin.

Chan JL, Abrahamson MJ.

Mayo Clin Proc. 2003 Apr;78(4):459-67. Review.

PMID:
12683698
8.

Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial.

Rosenstock J, Zinman B, Murphy LJ, Clement SC, Moore P, Bowering CK, Hendler R, Lan SP, Cefalu WT.

Ann Intern Med. 2005 Oct 18;143(8):549-58.

PMID:
16230721
10.

Overcoming psychological barriers to insulin use in type 2 diabetes.

Brunton SA, Davis SN, Renda SM.

Clin Cornerstone. 2006;8 Suppl 2:S19-26. Review.

PMID:
16939874
11.
12.

Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.

Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O, Zhadanova E, Starceva M, Kazakova E, Saifullina M, Shapiro I, Tarasov A, Al-Tayar B, Starkova N.

Clin Ther. 2007 Nov;29(11):2374-84.

PMID:
18158078
13.
14.

Type II diabetes mellitus.

Edelman SV.

Adv Intern Med. 1998;43:449-500. Review.

PMID:
9506190
15.

Benefits of timely basal insulin control in patients with type 2 diabetes.

Lovre D, Fonseca V.

J Diabetes Complications. 2015 Mar;29(2):295-301. doi: 10.1016/j.jdiacomp.2014.11.018. Epub 2014 Dec 5. Review.

16.

Identifying and addressing barriers to insulin acceptance and adherence in patients with type 2 diabetes mellitus.

Petznick AM.

J Am Osteopath Assoc. 2013 Apr;113(4 Suppl 2):S6-16. Erratum in: J Am Osteopath Assoc. 2013 Jul;113(7):507. Dosage error in article text.

PMID:
23545891
17.

Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM).

Abraira C, Henderson WG, Colwell JA, Nuttall FQ, Comstock JP, Emanuele NV, Levin SR, Sawin CT, Silbert CK.

Diabetes Care. 1998 Apr;21(4):574-9.

PMID:
9571345
18.

Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). A feasibility study.

Emanuele N, Klein R, Abraira C, Colwell J, Comstock J, Henderson WG, Levin S, Nuttall F, Sawin C, Silbert C, Lee HS, Johnson-Nagel N.

Diabetes Care. 1996 Dec;19(12):1375-81.

PMID:
8941467
19.

Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin.

Riddle M, Frias J, Zhang B, Maier H, Brown C, Lutz K, Kolterman O.

Diabetes Care. 2007 Nov;30(11):2794-9. Epub 2007 Aug 13.

PMID:
17698615
20.

Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus.

Ceglia L, Lau J, Pittas AG.

Ann Intern Med. 2006 Nov 7;145(9):665-75.

PMID:
17088580

Supplemental Content

Support Center